CD146
CD146 also known as Melanoma Cell Adhesion Molecule (MCAM) or Cell surface glycoprotein MUC18, is a protein that in humans is encoded by the MCAM gene. CD146 plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. As a cell adhesion molecule, CD146 plays a role in the interaction of activated endothelial cells with leukocytes, monocytes, and lymphocytes.
Structure[edit]
The CD146 protein is a member of the immunoglobulin superfamily, with a structure similar to that of the neural cell adhesion molecule. The protein is believed to be involved in cell-cell interactions or cell-substrate interactions. It is also thought to play a role in the process of angiogenesis, the formation of new blood vessels from pre-existing vessels.
Function[edit]
CD146 is involved in a variety of biological processes. It is involved in the adhesion and migration of cells, and also in the organization of cells into tissues. It is also involved in the process of angiogenesis, the formation of new blood vessels from pre-existing vessels. CD146 is also thought to play a role in the immune response, as it is involved in the interaction of activated endothelial cells with leukocytes, monocytes, and lymphocytes.
Clinical significance[edit]
CD146 has been found to be overexpressed in several types of cancer, including melanoma, breast cancer, and prostate cancer. It is thought that the overexpression of CD146 may contribute to the aggressive behavior of these cancers. CD146 is also thought to play a role in the development of cardiovascular disease, as it is involved in the formation of new blood vessels, a process that is often dysregulated in cardiovascular disease.
See also[edit]
- Cell adhesion
- Endothelial cells
- Leukocytes
- Monocytes
- Lymphocytes
- Angiogenesis
- Melanoma
- Breast cancer
- Prostate cancer
- Cardiovascular disease
References[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
